This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): MTBL-0036, MTBL 0036
MTBL0036 is a first-in-class anti-diabetic candidate acting both as an insulin sensitizer and an insulin secretagogue. MTBL0036 has the potential to correct the three major defects occurring in type 2 diabetes (increased hepatic glucose production, decreased muscle glucose consumption and deficient insulin secretion). Unlike metformin, MTBL0036 stimulates lactate and glutamine oxidation in liver cells. This effect occurs without an increase in the ATP level (MTBL0036 causes a mild uncoupling of oxidative phosphorylation in the liver but not in the kidney, brain and adipose tissue). MTBL0036 has the potential to correct the deficit of the mitochondrial function known to occur in the liver in type 2 diabetes.
MTBL0036 is a small molecule that is a mild uncoupler of the respiratory chain, which results in a decrease in (i) the cellular production and level of ATP and (ii) lactate gluconeogenesis, an ATP-dependent process.
Additional information available to subscribers only: